- Home
- WRBY vs ARQT Comparison
WRBY vs ARQT Comparison
Compare WRBY & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | ARQT |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WRBY | ARQT |
|---|---|---|
| Price | $25.54 | $24.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $26.50 | ★ $31.86 |
| AVG Volume (30 Days) | ★ 3.5M | 1.2M |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | 88.79 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $871,905,000.00 | $376,072,000.00 |
| Revenue This Year | $14.81 | $34.46 |
| Revenue Next Year | $15.98 | $29.77 |
| P/E Ratio | $2,490.00 | ★ N/A |
| Revenue Growth | 13.04 | ★ 91.34 |
| 52 Week Low | $13.63 | $11.86 |
| 52 Week High | $31.00 | $31.77 |
Technical Indicators
Market Signals| Indicator | WRBY | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 43.36 |
| Support Level | $25.23 | $22.26 |
| Resistance Level | $29.06 | $27.65 |
| Average True Range (ATR) | 1.77 | 1.54 |
| MACD | 0.27 | -0.18 |
| Stochastic Oscillator | 62.70 | 29.08 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.